top of page
Search
Jan 30
In a major article for Pharmaceutical Market Europe, SynaptixBio explains the science behind gene silencing technology
In a major article for Pharmaceutical Market Europe, SynaptixBio explains the science behind gene silencing technology
52 views
Jan 9
Dan Williams discusses SynaptixBio’s history, status, and aspirations in a major interview for leading US biotech podcast RAREcast
Dan Williams discusses SynaptixBio’s history, status, and aspirations in a major interview for leading US biotech podcast RAREcast
33 views
Dec 16, 2024
The market for ‘gene silencing’ therapies is set to explode
Dan Williams discusses the reasons behind this in FirstWord Pharma. Read his analysis here.
41 views
Oct 31, 2024
Amy Sheridan-Hill, co-founder of the H-ABC Foundation, and Dan Williams in major Mirror story about hopes for new drug
Read the Mirror news story about the H-ABC Foundation and SynaptixBio here.
63 views
Aug 23, 2024
SynaptixBio’s collaboration with leading global drug researcher Evotec featured in European Biotechnology Magazine
See full story of the SynaptixBio and Evotec collaboration here:
142 views
Jul 12, 2024
Dan Williams and Amy Sheridan-Hill, whose son Frankie suffers from H-ABC, interviewed for the Evening Standard.
Read the article here.
127 views
Jul 12, 2024
Dan Williams interviewed for leading podcast, Beyond Biotech
Click here to listen
26 views
Jun 11, 2024
In a major article, Dan Williams considers how to overcome obstacles in rare disease treatment
Rare Diseases, Common Problems by Dan Williams PhD – CEO SynaptixBio
42 views
Jun 11, 2024
Leading biotech appoints senior industry figure as Chief Medical Officer to define clinical strategy and oversee trials
SynaptixBio, the only company developing a treatment for a rare, deadly disease, has appointed Dr Uwe Meya to key position
119 views
Apr 30, 2024
Bioscience Today features major Dan Williams article about collaboration driving rare disease drug development
Bioscience Today has recently published Dan William’s latest article, indeed it’s the lead article on their website and in their magazine to
53 views
Apr 30, 2024
Dan Williams says Big Pharma could help accelerate market introduction for rare disease drugs
SynaptixBio, the only company developing treatment for a rare, deadly disease, says smaller biotech companies could partner with Big Pharma.
50 views
Apr 30, 2024
SynaptixBio awarded second FDA Orphan Drug Designation to boost search for rare disease therapies
SynaptixBio now aiming to develop treatment for second variant of TUBB4A leukodystrophy
193 views
Dec 23, 2023
BBC features TUBB4A leukodystrophy case study – Dan Williams contribution highlights lack of widespread awareness of rare diseases
Oxford company working on drug to treat rare brain disease By Sophia Seth & Daisy Stephens – BBC South A 10-year-old boy with a currently...
135 views
Dec 23, 2023
Dan Williams interviewed for prestigious journal - Major International Clinical Trials feature showcases SynaptixBio story
Dan Williams interviewed for prestigious journal
46 views
Dec 23, 2023
Leading biotech firm welcomes new NHS rapid diagnostic service for rare diseases, but says wider newborn screening is key
SynaptixBio, the only company developing a treatment for a rare but deadly leukodystrophy, says early diagnosis can improve the...
65 views
bottom of page